Adenosine Triphosphate (ATP) Assays Global Market Report 2024

The adenosine triphosphate (atp) assays market has grown rapidly in recent years. It will grow from $1.77 billion in 2023 to $1.97 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The expansion observed in the historical period can be credited to progress in biomedical research, advancements in drug discovery and development, heightened adoption in clinical diagnostics, growing demands for environmental monitoring, and an increased emphasis on cell-based assays.

The adenosine triphosphate (atp) assays market is expected to see rapid growth in the next few years. It will grow to $3.01 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The anticipated expansion in the forecast period can be attributed to the sustained growth of the biopharmaceutical industry, the widening implementation of personalized medicine approaches, heightened focus on ensuring food and beverage safety, technological innovations in assay platforms, and the increasing application in industrial processes. Major forecasted trends encompass advancements in ATP detection technologies, a growing demand for high-throughput screening, integration into clinical diagnostics, an emphasis on food and beverage safety testing, and expanded application in sports and performance monitoring.

The anticipated rise in the occurrence of cancer, chronic ailments, and infectious diseases is poised to drive the expansion of the adenosine triphosphate (ATP) assay market in the future. Cancer, characterized by unregulated cell growth, chronic conditions with prolonged persistence, and infectious diseases caused by pathogenic microorganisms, collectively contribute to the demand for ATP assays. These assays serve as crucial diagnostic tools, assessing cellular viability, detecting microbial contamination, monitoring treatment effectiveness, and evaluating metabolic and mitochondrial dysfunction. As an example, data from the World Health Organization in October 2022 indicated that approximately 10.6 million individuals were affected by tuberculosis (TB) in 2021, with 1.6 million fatalities recorded, including 187,000 HIV-positive individuals. Additionally, the International Diabetes Federation reported in 2021 that around 537 million adults were living with diabetes, a number projected to escalate to 783 million by 2045. Thus, the increasing prevalence of cancer, chronic ailments, and infectious diseases acts as a driving force behind the adenosine triphosphate (ATP) assay market.

The growing demand for personalized treatment approaches is expected to fuel the expansion of the adenosine triphosphate (ATP) assays market. Personalized treatments involve utilizing knowledge about an individual's unique genetic or protein makeup to prevent, detect, or treat diseases effectively. In the context of infectious disease management, ATP assays play a crucial role by assessing the efficacy of antimicrobial agents against specific pathogens, aiding in the selection of personalized treatment strategies. For instance, the US Food and Drug Administration (FDA) approved 12 personalized medicines in 2022, constituting around 34% of all newly approved therapeutic molecular entities, as reported by the Personalized Medicine Coalition. This surge in demand for personalized medicine underscores its pivotal role in driving the growth of the adenosine triphosphate (ATP) assays market.

The evolution of novel assays stands out as a prominent trend gaining momentum within the adenosine triphosphate (ATP) assay market. Key companies operating in this domain are introducing groundbreaking products, such as the SensiLux kit by BC Aplicaciones, a biotechnology firm based in Spain. The SensiLux kit is a unique testing solution designed for detecting microbial ATP in samples, utilizing bioluminescence for detection following sample pre-incubation. Its applications extend to areas such as food safety and contamination testing. Additionally, this offering includes ATP kits featuring advanced multi-injector automatic luminometers, proprietary control software, and future-oriented robot-based sample automation, providing customers with tailored solutions. BC Aplicaciones' programming and computer systems department have developed unique software to manage robot and luminometer operations.

Major players in the ATP assay market are directing their focus towards innovative solutions such as the AccuPoint Advanced Next Generation (NG) to bolster their market presence. This comprehensive sanitation monitoring system is engineered to validate and confirm the efficacy of sanitation programs by identifying organic residues lingering on surfaces and in liquids post-cleaning. For instance, in May 2021, Neogen Corporation, a US-based food safety entity, introduced the AccuPoint Advanced NG system, comprising a handheld instrument, innovative samplers, and data manager software. This system functions by measuring adenosine triphosphate (ATP), rendering the invisible visible and furnishing a reliable, consistent, and documented dataset on sanitation effectiveness. Offering automated data reporting, trend tracking, and audit functionalities, the AccuPoint Advanced NG system is designed to enhance sanitation testing across diverse sectors such as food safety, healthcare, and environmental monitoring.

In October 2021, Abcam plc, a UK-based biotechnology enterprise, completed the acquisition of BioVision Inc for $340 million. This strategic acquisition aimed to augment Abcam's capabilities, expanding its cellular assay portfolio in critical domains such as oncology, immuno-oncology, neuroscience, and epigenetics. The acquisition of BioVision, a US-based manufacturer specializing in ATP assays and test kits, empowered Abcam to gain a competitive edge and scale up its operations significantly within the market.

Major companies operating in the adenosine triphosphate (atp) assays market report are Merck KGaA, Thermo Fisher Scientific Inc., PerkinElmer Inc., Lonza Group, Promega Corporation, Agilent Technologies Inc., Abcam plc, Danaher Corporation, 3M Co., Geno Technology Inc., NEOGEN Corporation, Biomerieux SA, AAT Bioquest Inc., MBL International Corporation, Charm Sciences Inc., Cell Signaling Technology Inc., Cayman Chemical Company, Vazyme Biotech Co. Ltd., SignalChem Lifesciences Corporation, Kaneka Corporation, Novus Biologicals LLC, NANOGEN Biotechnologies Inc., Nacalai Tesque Inc., MoBiTec GmbH, Lumigen Inc., Jena Bioscience GmbH, Goryo Chemical Inc., Cosmo Bio Co. Ltd., BPS Bioscience Inc., BioTek Instruments Inc.

North America was the largest region in the adenosine triphosphate (ATP) assays market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adenosine triphosphate (atp) assays market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adenosine triphosphate (atp) assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of ATP assays include luminometric ATP assays, enzymatic ATP assays, bioluminescence resonance energy transfer (BRET) ATP assays, cell-based ATP assays, among others. Luminometric ATP assays, specifically, leverage bioluminescence principles to measure ATP levels in samples. They are widely used in research, drug discovery, and biomedical applications for assessing cellular energy status, measuring enzymatic activity, evaluating cell viability, and screening ATP-modulating compounds. These assays consist of essential components such as consumables, accessories, and instruments utilized across diverse fields including drug discovery and development, clinical diagnostics, environmental testing, and food safety and quality assessment. Their applications extend to various end-users such as pharmaceutical and biotechnology companies, the food and beverage industry, hospitals, diagnostics laboratories, as well as academic and research institutions.

The adenosine triphosphate (ATP) assays market research report provides adenosine triphosphate (ATP) assays market statistics, including adenosine triphosphate (ATP) assays industry global market size, regional shares, competitors with an adenosine triphosphate (ATP) assays market share, detailed adenosine triphosphate (ATP) assays market segments, market trends and opportunities, and any further data you may need to thrive in the adenosine triphosphate (ATP) assays industry. This adenosine triphosphate (ATP) assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adenosine triphosphate (ATP) assays market consists of revenues earned by entities by providing testing services related to colorimetric and fluorescent assays. The market value includes the value of related goods sold by the service provider or included within the service offering. The adenosine triphosphate (ATP) assays market also includes sales of luminometer, and chemiluminescent which are used in adenosine triphosphate (ATP) assay services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.